Λίστα αντικειμένων
We discussed the use of Tki after allo hct for ph + ALL and our current practice.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Kostopoulou
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Kostopoulou
Leukemia. 2020 Nov 17; A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. PMID: 33204013 |